Matches in SemOpenAlex for { <https://semopenalex.org/work/W2260862034> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2260862034 endingPage "ix27" @default.
- W2260862034 startingPage "ix27" @default.
- W2260862034 abstract "ABSTRACT Hormone receptor positive (HR+) breast cancers can be separated by molecular subtyping into luminal A breast cancer (LUM A), which is more prevalent though less aggressive, and luminal B breast cancer (LUM B), which is associated with higher grade, increased proliferation rates, and an overall poorer prognosis. Other than genetic molecular subtyping, which can be expensive and not readily available, it may be possible to differentiate between these two subgroups using immunohistochemical assessment of the proliferative marker Ki67, as reported by Cheang et al, where a cut off of Ki67 14% was used. This method of assessment demonstrated utility in providing prognostic information, however the false positive and false negative rates were around 25%, suggesting there is significant room for improvement within such a method, and thus highlighting an area for ongoing research. Methodology aside, differentiation of HR+ breast cancers by molecular subgroups is critical, in order to identify appropriate treatment options for patients. Generally, endocrine therapy alone would be recommended for LUM A, which carries an excellent ten year breast cancer specific survival rate of approximately 90%. However, tumor dormancy and late recurrences beyond 10 years are characteristic of LUM A. There is a significant lack of knowledge of the mechanisms behind tumor dormancy, highlighting a crucial area for further research. Additionally, the optimal manner and duration of endocrine therapy in either pre- or postmenopausal women is, as yet, unknown; extension of endocrine treatment beyond 5 or even 10 years, as well as the most effective endocrine therapy agent, requires ongoing study to better define treatment algorithms for LUM A. LUM B, which is inherently more aggressive, requires more aggressive therapy and thus is generally treated with both endocrine therapy and chemotherapy, though this approach is not always effective. Potential alternate or additional treatment options may include targeting of other pathways of importance in this subgroup. This therefore requires firstly identification of pathways active in LUM B, and secondly, development and assessment of targeted agents against these pathways. The utility of inhibitors against mTOR, PI3K or IGFR-1 is of particular interest. Disclosure All authors have declared no conflicts of interest." @default.
- W2260862034 created "2016-06-24" @default.
- W2260862034 creator A5007550358 @default.
- W2260862034 creator A5012991748 @default.
- W2260862034 creator A5031915637 @default.
- W2260862034 creator A5041495974 @default.
- W2260862034 creator A5068704607 @default.
- W2260862034 creator A5075862226 @default.
- W2260862034 creator A5077979726 @default.
- W2260862034 creator A5089361418 @default.
- W2260862034 date "2012-09-01" @default.
- W2260862034 modified "2023-10-05" @default.
- W2260862034 title "Introduction: Luminal A and B: How Curable are they?" @default.
- W2260862034 doi "https://doi.org/10.1093/annonc/mds371" @default.
- W2260862034 hasPublicationYear "2012" @default.
- W2260862034 type Work @default.
- W2260862034 sameAs 2260862034 @default.
- W2260862034 citedByCount "3" @default.
- W2260862034 countsByYear W22608620342015 @default.
- W2260862034 countsByYear W22608620342019 @default.
- W2260862034 crossrefType "journal-article" @default.
- W2260862034 hasAuthorship W2260862034A5007550358 @default.
- W2260862034 hasAuthorship W2260862034A5012991748 @default.
- W2260862034 hasAuthorship W2260862034A5031915637 @default.
- W2260862034 hasAuthorship W2260862034A5041495974 @default.
- W2260862034 hasAuthorship W2260862034A5068704607 @default.
- W2260862034 hasAuthorship W2260862034A5075862226 @default.
- W2260862034 hasAuthorship W2260862034A5077979726 @default.
- W2260862034 hasAuthorship W2260862034A5089361418 @default.
- W2260862034 hasBestOaLocation W22608620341 @default.
- W2260862034 hasConcept C71924100 @default.
- W2260862034 hasConceptScore W2260862034C71924100 @default.
- W2260862034 hasLocation W22608620341 @default.
- W2260862034 hasOpenAccess W2260862034 @default.
- W2260862034 hasPrimaryLocation W22608620341 @default.
- W2260862034 hasRelatedWork W1506200166 @default.
- W2260862034 hasRelatedWork W1995515455 @default.
- W2260862034 hasRelatedWork W2048182022 @default.
- W2260862034 hasRelatedWork W2080531066 @default.
- W2260862034 hasRelatedWork W2604872355 @default.
- W2260862034 hasRelatedWork W2748952813 @default.
- W2260862034 hasRelatedWork W2899084033 @default.
- W2260862034 hasRelatedWork W3031052312 @default.
- W2260862034 hasRelatedWork W3032375762 @default.
- W2260862034 hasRelatedWork W3108674512 @default.
- W2260862034 hasVolume "23" @default.
- W2260862034 isParatext "false" @default.
- W2260862034 isRetracted "false" @default.
- W2260862034 magId "2260862034" @default.
- W2260862034 workType "article" @default.